JP Morgan Chase
AMLX icon

JP Morgan Chase’s Amylyx Pharmaceuticals AMLX Stock Holding History

JP Morgan Chase’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,300
Closed -$122K – 7373
2023
Q4 		$122K Buy
+8,300
New +$127K ﹤0.01% 5645

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

JP Morgan Chase's AMLX Position: Q1 2026 in Review

JP Morgan Chase increased its Amylyx Pharmaceuticals (AMLX) stake by 140% in Q1 2026, buying an estimated $1.31M and bringing the position to 159,663 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #4084.

JP Morgan Chase first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $4.1M in Q2 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • JP Morgan Chase held 159,663 shares of Amylyx Pharmaceuticals worth $2.04M as of Q1 2026.
  • JP Morgan Chase bought 93,116 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.31M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4084 holding.
  • JP Morgan Chase first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • JP Morgan Chase's Amylyx Pharmaceuticals position peaked at $4.1M in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.